Mechanistic studies on metabolic chiral inversion of 4-(4-methylphenyl)-2-methylthiomethyl-4-oxobutanoic acid (KE-748), an active metabolite of the new anti-rheumatic agent 2-acetylthiomethyl-4-(4-methylphenyl)-4-oxobutanoic acid (KE-298), in rats

Biochemical Pharmacology

Volumn 53, Issue 2, 1997, Pages 179-187

  Yoshida, Hideo ^a   Kohno, Yoshiro ^b   Endo, Hiromi ^b   Yamaguchi, Jun Ichi ^b   Fukushima, Kiyomi ^b   Suwa, Toshio ^b   Hayashi, Masahiro ^b  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

^b NONE

Author keywords

anti rheumatic drug; chiral inversion; CoA ligase; ibuprofen; KE 298; rat

Indexed keywords

3 (4 METHYLBENZOYL) 2 (METHYLTHIOMETHYL)PROPIONIC ACID; ADENOSINE TRIPHOSPHATE; ANTIRHEUMATIC AGENT; BENZOIC ACID; CLOFIBRIC ACID; COENZYME A; DRUG METABOLITE; ESONARIMOD; FATTY ACID; IBUPROFEN; LIGASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHIRALITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; ISOTOPE LABELING; LIVER CELL; LIVER METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIRHEUMATIC AGENTS; CELL-FREE SYSTEM; COENZYME A LIGASES; FATTY ACIDS; IBUPROFEN; LIVER; MALE; PHENYLPROPIONATES; RATS; RATS, WISTAR; REPRESSOR PROTEINS; SACCHAROMYCES CEREVISIAE PROTEINS; STEREOISOMERISM;

EID: 0031021221     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00658-2     Document Type: Article

References (38)

1. Kameo K, Ogawa K, Takeshita K, Nakaike S, Tomisawa K and Sota K, Studies on antirheumatic agents: 3-Benzoylpropionic acid derivatives. Chem Pharm Bull (Tokyo) 36: 2050-2060, 1988.
2. Takeshita K, Fukazawa I, Futaki N, Kameo K, Tomisawa K, Otomo S and Aihara H, Immunopharmacological studies of new 3-benzoyl-4-mercaptobutyric acids. Arzeimittel forschung 38: 537-542, 1988.
3. Yoshida H, Kohno Y, Endo H, Hasegawa M, Yamaguchi J, Tomisawa K and Suwa T, Identification of metabolites of KE-298, a new antirheumatic drug, and its physiological properties in rats. Biol Pharm Bull 19: 424-429, 1996.
4. 14C]-labeled KE-298, a new antirheumatic drug, in rats. Chirality 8: 258-263, 1996.
5. Yoshida H, Kohno Y, Endo H, Ohmi N, Fukushima K, Suwa T and Hayashi M, Stereoselective disposition and chiral inversion of KE-298, a new antirheumatic drug, in rats. Chirality, in press.
6. Schmahl HJ, Nau H and Neubert D, The enantiomers of the teratogenic thalidomide analogue EM12: Chiral inversion and plasma pharmacokinetics in the marmoset monkey. Arch Toxicol 62: 200-204, 1988.
7. Yokoyama T, Fukuda K, Mori S, Ogawa M and Nagasawa K, Determination of tolperisone enantiomers in plasma and their disposition in rats. Chem Pharm Bull (Tokyo) 40: 272-274, 1992.
8. Yamada H, Pharmacokinetics of chiral drugs. Farumashia 25: 329-332, 1989.
9. Jamali F, Pharmacokinetics of enantiomers of chiral nonsteroidal anti-inflammatory drugs. Eur J Drug Metab Pharmacokinet 13: 1-9, 1988.
10. Mills RFN, Adams SS, Cliffe EE, Dickinson W and Nicholson JS, The metabolism of ibuprofen. Xenobiotica 3: 589-598, 1973.
11. Berry BW and Jamali F, Presystemic and systemic chiral inversion of R-(-)-fenoprofen in the rat. J Pharmacol Exp Ther 258: 695-701, 1991.
12. Rubin A, Knadler MP, Ho PPK, Bechtol LD and Wolen RL, Stereoselective inversion of (R)-fenoprofen to (S)-fenoprofen in humans. J Pharm Sci 74: 82-84, 1985.
13. Knights KM, Drew R and Meffin PJ, Enantiospecific formation of fenoprofen coenzyme A thioester in vitro. Biochem Pharmacol 37: 3539-3542, 1988.
14. Knihinicki RD, Williams KM and Day RO, Chiral inversion of 2-arylpropionic acid non-steroidal anti-inflammatory drugs - 1. In vitro studies of ibuprofen and flurbiprofen. Biochem Pharmacol 38: 4389-4395, 1989.
15. Tracy TS and Hall SD, Determination of the epimeric composition of ibuprofen-CoA. Anal Biochem 195: 24-29, 1991.
16. Porubek DJ, Sanins SM, Stephens JR, Grillo MP, Kaiser DG, Halstead GW, Adams WJ and Baillie TA, Metabolic chiral inversion of flurbiprofen-CoA in vitro. Biochem Pharmacol 42: R1-R4, 1991.
17. Knihinicki RD, Day RO and Williams KM, Chiral inversion of 2-arylpropionic acid non-steroidal anti-inflammatory drugs - II. Racemization and hydrolysis of (R)-and (S)-ibuprofen-CoA thioesters. Biochem Pharmacol 42: 1905-1911, 1991.
18. Tracy TS, Wirthwein DP and Hall SD, Metabolic inversion of (R)-ibuprofen. Formation of ibuprofenyl-coenzyme A. Drug Metab Dispos 21: 114-120, 1993.
19. Nakamura Y, Yamaguchi T, Takahashi S, Hashimoto S, Iwatani K and Nakagawa Y, Optical isomerization mechanism of R(-)-hydratropic acid derivatives. J Pharmacobiodyn 4: s-1, 1981.
20. Chen C-S, Chen T and Shieh W-R, Metabolic stereoisomeric inversion of 2-arylpropionic acid. On the mechanism of ibuprofen epimerization in rats. Biochim Biophys Acta 1033: 1-6, 1990.
21. Sanins SM, Adams WJ, Kaiser DG, Halsread GW, Hosley J, Barnes H and Baillie TA, Mechanistic studies on the metabolic chiral inversion of R-ibuprofen in the rat. Drug Metab Dispos 19: 405-410, 1991.
22. Moldeus P, Hogberg J and Orrenius S, Isolation and use of liver cells. Methods Enzymol 52: 60-71, 1978.
23. Knights KM, Addinal TF and Roberts BJ, Enhanced chiral inversion of R-ibuprofen in liver from rats treated with clofibric acid. Biochem Pharmacol 41: 1775-1777, 1991.
24. Müller S, Mayer JM, Etter J-C and Testa B, Influence of palmitate and benzoate on the unidirectional chiral inversion of ibuprofen in isolated rat hepatocytes. Biochem Pharmacol 44: 1468-1470, 1992.
25. Olsson DM and Nelson LS, The Nelder-Mead Simplex procedure for function minimization. Technometrics 17: 45-51, 1975.
26. Simmonds RG, Woodage TJ, Duff SM and Green JN, Stereospecific inversion of R-(-)-benoxaprofen in rat and man. Eur J Drug Metab Pharmacokinet 5: 169-172, 1980.
27. Nakamura Y and Yamaguchi T, Stereoselective metabolism of 2-phenylpropionic acids in rat. I. In vitro studies on the stereoselective isomerization and glucuronidation of 2-phenyl-propionic acid. Drug Metab Dispos 15: 529-534, 1987.
28. Hutt A and Caldwell J, The metabolic chiral inversion of 2-arylpropionic acid - a novel route with pharmacological consequences. J Pharm Pharmacol 35: 693-704, 1983.
29. Mayer JM, Bartolucci C, Maitre JM and Testa B, Metabolic chiral inversion of anti-inflammatory 2-arylpropionates: Lack of reaction in liver homogenates, and study of methine proton acidity. Xenobiotica 18: 533-543, 1988.
30. Aas M, Organ and subcellular distribution of fatty acid activating enzymes in the rat. Biochim Biophys Acta 231: 32-47, 1971.
31. Kawashima Y, Hirose A and Kozuka H, Modification by clofibric acid of acyl composition of glycerolipids in rat liver. Biochim Biophys Acta 795: 543-551, 1984.
32. Alegret M, Ferrando R, Vázquez M, Adzet T, Merlos M and Laguna JC, Relationship between plasma lipids and palmitoyl-CoA hydrolase and synthetase activities with peroxisomal proliferation in rats treated with fibrates. Br J Pharmacol 112: 551-556, 1994.
33. Knights KM and Roberts BJ, Xenobiotic acyl-CoA formation: Evidence of kinetically distinct hepatic microsomal longchain fatty acid and nafenopin-CoA ligases. Chem Biol Interact 90: 215-223, 1994.
34. Yao KW, Mao LF, Luo MJ and Schulz H, The relationship between mitochondrial activation and toxicity of some substituted carboxylic acids. Chem Biol Interact 90: 225-234, 1994.
35. Williams K, Day R, Knihinicki R and Duffield A, The stereoselective uptake of ibuprofen enantiomers into adipose tissue. Biochem Pharmacol 35: 3403-3405, 1986.
36. Caldwell J and Marsh MV, Interrelationships between xenobiotic metabolism and lipid biosynthesis. Biochem Pharmacol 32: 1667-1672, 1983.
37. Mayer JM, Testa B, Roy-de Vos M, Audergon C and Etter JC, Interactions between the in vitro metabolism of xenobiotics and fatty acids. The case of ibuprofen and other chiral profens. Arch Toxicol Suppl 17: 499-513, 1995.
38. Hilal R and El-Aaser AM, A comparative quantum chemical study of methyl acetate and S-methyl thioacetate. Toward an understanding of the biochemical reactivity of ester of coenzyme A. Biophys Chem 22: 145-150, 1985.